

**SEQUENT SCIENTIFIC LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2012**

(₹ in Lakhs)

S.No.	Particulars	STANDALONE					
		Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-12 UNAUDITED	30-Sep-12 UNAUDITED	31-Dec-11 UNAUDITED	31-Dec-12 UNAUDITED	31-Dec-11 UNAUDITED	31-Mar-12 AUDITED
<b>Part-I</b>							
<b>1</b>	<b>Income from operations</b>						
a	Net Sales / Income from Operations (net of excise duty)	8,269.20	6,295.80	7,492.00	21,731.20	23,272.90	33,188.00
b	Other Operating Income	4.00	3.60	-	22.50	-	55.20
	<b>Total income from operations (net)</b>	<b>8,273.20</b>	<b>6,299.40</b>	<b>7,492.00</b>	<b>21,753.70</b>	<b>23,272.90</b>	<b>33,243.20</b>
<b>2</b>	<b>Expenses</b>						
a	Cost of materials consumed	5,055.70	3,610.80	4,005.81	11,955.60	13,256.22	18,074.80
b	Purchase of stock-in-trade	323.20	253.60	173.79	734.70	597.38	851.30
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,025.60)	(573.70)	37.30	(1,157.50)	(373.00)	61.20
d	Employee benefits expenses	748.40	767.60	581.80	2,123.80	1,900.80	2,543.70
e	Depreciation and amortisation expenses	612.60	738.00	672.07	1,912.20	1,573.80	2,102.80
f	Other expenses	3,053.40	2,447.90	2,066.48	7,663.30	6,520.83	8,165.00
	<b>Total expenses</b>	<b>8,767.70</b>	<b>7,244.20</b>	<b>7,537.25</b>	<b>23,232.10</b>	<b>23,476.03</b>	<b>31,798.80</b>
<b>3</b>	<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(494.50)</b>	<b>(944.80)</b>	<b>(45.25)</b>	<b>(1,478.40)</b>	<b>(203.13)</b>	<b>1,444.40</b>
4	Other Income	66.10	1,008.70	146.40	226.30	818.40	1,132.70
<b>5</b>	<b>Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3±4)</b>	<b>(428.40)</b>	<b>63.90</b>	<b>101.15</b>	<b>(1,252.10)</b>	<b>615.27</b>	<b>2,577.10</b>
<b>6</b>	<b>Finance cost</b>	<b>783.20</b>	<b>691.00</b>	<b>697.22</b>	<b>2,210.50</b>	<b>2,035.47</b>	<b>2,826.50</b>
<b>7</b>	<b>Profit/(Loss) from ordinary activities after finance cost but before exceptional Items (5±6)</b>	<b>(1,211.60)</b>	<b>(627.10)</b>	<b>(596.07)</b>	<b>(3,462.60)</b>	<b>(1,420.20)</b>	<b>(249.40)</b>
8	Exceptional Items	-	-	-	-	-	-
<b>9</b>	<b>Profit/(Loss) from ordinary activities before tax (7±8)</b>	<b>(1,211.60)</b>	<b>(627.10)</b>	<b>(596.07)</b>	<b>(3,462.60)</b>	<b>(1,420.20)</b>	<b>(249.40)</b>
10	Tax Expense	(83.80)	(209.00)	(309.74)	(398.70)	(133.50)	(396.40)
<b>11</b>	<b>Net Profit/(Loss) from Ordinary activities after tax (9±10)</b>	<b>(1,127.80)</b>	<b>(418.10)</b>	<b>(286.33)</b>	<b>(3,063.90)</b>	<b>(1,286.70)</b>	<b>147.00</b>
12	Extraordinary items	-	-	-	-	-	-
<b>13</b>	<b>Net Profit/(Loss) for the period(11±12)</b>	<b>(1,127.80)</b>	<b>(418.10)</b>	<b>(286.33)</b>	<b>(3,063.90)</b>	<b>(1,286.70)</b>	<b>147.00</b>
14	Paid-up equity share capital (Face Value per share Rs.10 each)	2,363.50	2,193.50	2,193.50	2,363.50	2,193.50	2,193.50
15	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	10,537.20
<b>16.i</b>	<b>Earnings Per Share before Extraordinary Items for the period (Non-Annualised)</b>						
	Basic (Rs.)	(4.86)	(1.91)	(1.31)	(13.71)	(5.87)	0.67
	Diluted (Rs.)	(4.86)	(1.91)	(1.31)	(13.71)	(5.87)	0.67
<b>16.ii</b>	<b>Earnings Per Share after Extraordinary Items for the period (Non-Annualised)</b>						
	Basic (Rs.)	(4.86)	(1.91)	(1.31)	(13.71)	(5.87)	0.67
	Diluted (Rs.)	(4.86)	(1.91)	(1.31)	(13.71)	(5.87)	0.67
<b>Part-II</b>							
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	<b>Public Shareholding</b>						
	No. of Shares	9,500,680	9,500,680	9,745,212	9,500,680	9,745,212	9,745,212
	% of Share Holding	40.20%	43.31%	44.43%	40.20%	44.43%	44.43%
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>						
a)	Pledged / Encumbered						
1.	No. of shares	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
2.	Percentage of shares (as a % of the total shareholding of promoter & promoter group)	7.07%	8.04%	8.20%	7.07%	8.20%	8.20%
3.	Percentage of shares (as a % of the total share capital of the company)	4.23%	4.56%	4.56%	4.23%	4.56%	4.56%
b)	Non-encumbered						
1.	No. of shares	13,134,511	11,434,511	11,189,979	13,134,511	11,189,979	11,189,979
2.	Percentage of shares(as a % of the total shareholding of promoter & promoter group)	92.93%	91.96%	91.80%	92.93%	91.80%	91.80%
3.	Percentage of shares (as a % of the total share capital of the company)	55.57%	52.13%	51.01%	55.57%	51.01%	51.01%
<b>B</b>	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the quarter						NIL
	Received during the quarter						NIL
	Disposed of during the quarter						NIL
	Remaining unresolved at the end of the quarter						NIL

**Notes:**

- The unaudited financial results were taken on record by the Board of Directors at its meeting held on February 14, 2013.
- The Statutory Auditors have performed a limited review of the standalone financial results for the period ended as on December 31, 2012 of the Company as required by Clause 41 of the Listing Agreement.
- Segment Results

The Company has identified Pharmaceuticals and Specialty Chemicals as its business segments, Segments have been identified taking in to account the nature of products, the differing risks and returns, the organisational structure and the internal reporting system.

Sl. No	Particulars	Quarter Ended		Nine Months Ended		Year Ended	
		31-Dec-12 UNAUDITED	30-Sep-12 UNAUDITED	31-Dec-11 UNAUDITED	31-Dec-12 UNAUDITED	31-Dec-11 UNAUDITED	31-Mar-12 AUDITED
1	<b>Segment Revenue</b>						
	a) Pharmaceuticals	6,719.86	5,066.58	6,300.99	18,034.77	19,883.92	28,213.31
	b) Specialty Chemicals	1,553.34	1,232.82	1,191.01	3,718.93	3,388.98	5,029.89
	<b>Net Sales /Income from Operations</b>	<b>8,273.20</b>	<b>6,299.40</b>	<b>7,492.00</b>	<b>21,753.70</b>	<b>23,272.90</b>	<b>33,243.20</b>
2	<b>Segment Results</b>						
	<b>Profit or Loss before Tax and Interest from Each Segment</b>						
	a) Pharmaceuticals	(635.21)	(1.94)	(478.68)	(1,321.14)	(165.93)	1,109.73
	b) Specialty Chemicals	353.16	237.42	223.33	482.15	631.73	1,085.62
	<b>Total</b>	<b>(282.05)</b>	<b>235.48</b>	<b>(255.35)</b>	<b>(838.99)</b>	<b>465.80</b>	<b>2,195.35</b>
	Less (i) Finance Cost	783.20	691.00	697.22	2,210.50	2,035.47	2,826.50
(ii) other unallocable expenditure net off unallocable income	146.35	171.58	(356.50)	413.11	(149.47)	(381.75)	
	<b>Total Profit Before Tax</b>	<b>(1,211.60)</b>	<b>(627.10)</b>	<b>(596.07)</b>	<b>(3,462.60)</b>	<b>(1,420.20)</b>	<b>(249.40)</b>
3	<b>Capital Employed</b>						
	a) Pharmaceuticals	26,976.16	24,833.43	22,326.64	26,976.16	22,326.64	17,816.86
	b) Specialty Chemicals	1,723.60	890.28	3,215.80	1,723.60	3,215.80	2,844.96
	c) Unallocated	(16,919.26)	(14,355.11)	(14,232.34)	(16,919.26)	(14,232.34)	(7,990.52)
	<b>Total</b>	<b>11,780.50</b>	<b>11,368.60</b>	<b>11,310.10</b>	<b>11,780.50</b>	<b>11,310.10</b>	<b>12,671.30</b>

- Figures for previous periods have been regrouped and rearranged, wherever necessary, to confirm to the relevant current period classification.

For Sequent Scientific Limited

Place: Bangalore

Dr. Gautam Kumar Das

Date : February 14, 2013

Executive Director